<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11859606</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.539</article-id><article-id pub-id-type="other">EPP0377</article-id><article-id pub-id-type="pii">S092493382400539X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Real-world effectiveness and safety of esketamine intranasal spray combined with treatment-as-usual in psychiatric inpatients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kavakbasi</surname><given-names>E.</given-names></name><xref rid="aff1217" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0400" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yilmaz</surname><given-names>M.</given-names></name><xref rid="aff1217" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bulut</surname><given-names>&#x000d6;.</given-names></name><xref rid="aff1217" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Berndt</surname><given-names>H.</given-names></name><xref rid="aff1217" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Baune</surname><given-names>B. T.</given-names></name><xref rid="aff1217" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1218" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff1219" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1217">
<sup>1</sup>Department of Psychiatry, <institution>University Hospital M&#x000fc;nster, University of M&#x000fc;nster</institution>, <city>M&#x000fc;nster</city>, <country>Germany</country>
</aff><aff id="aff1218">
<sup>2</sup>Department of Psychiatry, Melbourne Medical School, <institution>The University of Melbourne</institution>, <city>Melbourne</city>
</aff><aff id="aff1219">
<sup>3</sup>The Florey Institute of Neuroscience and Mental Health, <institution>The University of Melbourne</institution>, <city>Parkville</city>, <country>
Australia</country>
</aff><author-notes><corresp id="cor0400">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="514">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S254</fpage><lpage>S255</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400539Xa.pdf"/><abstract><sec id="sec2401"><title>Introduction</title><p>Esketamine intranasal spray has been approved in both the USA and EU as a novel treatment in patients with treatment-resistant major depression (TRD) and for the management of acute depressive emergencies during the course of major depressive disorder (MDD). Real-world data on the effectiveness and safety of esketamine nasal spray in clinical use are limited.</p></sec><sec id="sec2402"><title>Objectives</title><p>To investigate the clinical effects and safety of esketamine nasal spray on depression severity and suicidal ideation during inpatient treatment in n=76 patients in a German university hospital.</p></sec><sec id="sec2403"><title>Methods</title><p>In this retrospective chart review, we analyzed the change in depression severity and safety after a treatment series with esketamine nasal spray combined with treatment-as-usual in patients with treatment-resistant depression (TRD) in inpatient treatment setting of a University Hospital. Depression severity has been rated with the Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale (MADRS) as well as with the BDI-II (Beck Depression Inventory-Second Edition) before and after the treatment series. The intensity of suicidal ideation has been evaluated using MADRS item 10 on suicidal thoughts.</p></sec><sec id="sec2404"><title>Results</title><p>
A total of 76 patients have been included (women 55.3, n=42) in this analysis. Mean BDI-II pre-treatment was 37.6 and mean MADRS was 33.6 corresponding to severe depression. Mean score on item-10 pre-treatment was 2.4 (median 2.0). On average patients received 10.9 sessions (standard deviation 4.2, median 11.0) of esketamine nasal spray (min 1, max. 19 sessions). There was clear improvement after the treatment series in both the BDI-II (mean change -10.1, p &#x0003c; 0.001) as well as in MADRS score (mean reduction -10.0, p &#x0003c; 0.001). Suicidal ideation on item-10 also decreased significantly (-0.9, p &#x0003c; 0.001). The effect sizes were large for all three measures: Cohen&#x02019;s d 1.050 for BDI-II; 0.986 for MADRS and 0.742 for changes in suicidal ideation. Overall, esketamine treatment was well tolerated. In five cases esketamine treatment has been terminated early (after a mean of 3.4 sessions) due to dissociations (n=4; 5.3%) or due to non-response (n=1).</p></sec><sec id="sec2405"><title>Conclusions</title><p>
Esketamine nasal spray is a novel effective and safe treatment option, which leads to significant decrease in depression severity as well as in suicidal ideation. More data from real-world patients are needed to position esketamine in the algorithm of depression treatment.&#x000a0;Rate of treatment discontinuation due to side-effects in this study was comparable to those in other esketamine studies (4.2% in Reif et al, NEJM, 2023).</p></sec><sec id="sec2406"><title>Disclosure of Interest</title><p>None Declared
</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>